Patisiran treatment for ATTR cardiac amyloidosis: 18-month results of the phase 3 APOLLO-B study

Back

HFA Premium Access

Patisiran treatment for ATTR cardiac amyloidosis: 18-month results of the phase 3 APOLLO-B study

Session: Late breaking clinical trials: chronic HF and cardiomyopathies

Topic: Pharmacotherapy

Speaker: Professor M. Fontana (London, GB)

Event: Heart Failure 2023

Congress Presentation

Add to my library

About the speaker

Professor Marianna Fontana

University College London, London (United Kingdom of Great Britain & Northern Ireland)

59 presentations

36 followers

5 more presentations in this session

Remote Hemodynamic Monitoring of Pulmonary Artery Pressures in Patients with Chronic Heart Failure (MONITOR-HF): A randomized controlled clinical trial

Speaker: Professor J. Brugts (Rotterdam, NL)

Access

Slides

Video

Phase 1b evaluation of safety and activity of JK07 in heart failure with reduced ejection fraction

Speaker: Professor W. Tang (Cleveland, US)

Access

Slides

Video

TRACER-HF: Trientine-HCL for treatment of heart failure and reduced ejection fraction

Speaker: Professor J. Januzzi (Boston, US)

Access

Slides

Video

REDWOOD-HCM-Cohort 4: Aficamten in non-obstructive HCM

Speaker: Doctor A. Masri (Portland, US)

Access

Slides

Video

Primary results of the Phase Ib proof-of-concept study of NI006, a recombinant human antibody to deplete amyloid deposits in ATTR-cardiomyopathy

Speaker: Doctor P. Garcia-Pavia (Majadahonda, ES)

Access

Slides

Video

Access the full session

Late breaking clinical trials: chronic HF and cardiomyopathies

Speakers: Professor M. Fontana, Professor J. Brugts, Professor W. Tang, Professor J. Januzzi, Doctor A. Masri...

Access

Video

About the event

Heart Failure 2023

20 May - 23 May 2023

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources